These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 33677227)
1. Docking-based virtual screening studies aiming at the covalent inhibition of SARS-CoV-2 M Soulère L; Barbier T; Queneau Y Comput Biol Chem; 2021 Jun; 92():107463. PubMed ID: 33677227 [TBL] [Abstract][Full Text] [Related]
2. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease. Hajbabaie R; Harper MT; Rahman T Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721 [TBL] [Abstract][Full Text] [Related]
3. In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking. Vázquez-Mendoza LH; Mendoza-Figueroa HL; García-Vázquez JB; Correa-Basurto J; García-Machorro J Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409348 [TBL] [Abstract][Full Text] [Related]
4. Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV-2 Main Protease. Gahlawat A; Kumar N; Kumar R; Sandhu H; Singh IP; Singh S; Sjöstedt A; Garg P J Chem Inf Model; 2020 Dec; 60(12):5781-5793. PubMed ID: 32687345 [TBL] [Abstract][Full Text] [Related]
5. Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay. Pitsillou E; Liang J; Ververis K; Hung A; Karagiannis TC J Mol Graph Model; 2021 May; 104():107851. PubMed ID: 33556646 [TBL] [Abstract][Full Text] [Related]
6. Apigenin analogues as SARS-CoV-2 main protease inhibitors: Farhat A; Ben Hlima H; Khemakhem B; Ben Halima Y; Michaud P; Abdelkafi S; Fendri I Bioengineered; 2022 Feb; 13(2):3350-3361. PubMed ID: 35048792 [TBL] [Abstract][Full Text] [Related]
7. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening. Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740 [TBL] [Abstract][Full Text] [Related]
8. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an Awoonor-Williams E Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834 [TBL] [Abstract][Full Text] [Related]
9. Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro/3CLpro) and Human Cathepsin-L. Costanzi E; Kuzikov M; Esposito F; Albani S; Demitri N; Giabbai B; Camasta M; Tramontano E; Rossetti G; Zaliani A; Storici P Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769210 [TBL] [Abstract][Full Text] [Related]
10. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV. Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605 [TBL] [Abstract][Full Text] [Related]
11. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166 [TBL] [Abstract][Full Text] [Related]
12. An Updated Review on SARS-CoV-2 Main Proteinase (M Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134 [TBL] [Abstract][Full Text] [Related]
13. Ensemble docking based virtual screening of SARS-CoV-2 main protease inhibitors. Fomina AD; Uvarova VI; Kozlovskaya LI; Palyulin VA; Osolodkin DI; Ishmukhametov AA Mol Inform; 2024 Aug; 43(8):e202300279. PubMed ID: 38973780 [TBL] [Abstract][Full Text] [Related]
14. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease. Mandour YM; Zlotos DP; Alaraby Salem M J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680 [TBL] [Abstract][Full Text] [Related]
15. An integrated metabolomic and proteomic approach for the identification of covalent inhibitors of the main protease (M Baron G; Borella S; Della Vedova L; Vittorio S; Vistoli G; Carini M; Aldini G; Altomare A Talanta; 2023 Jan; 252():123824. PubMed ID: 36027618 [TBL] [Abstract][Full Text] [Related]
16. Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease. Marinho EM; Batista de Andrade Neto J; Silva J; Rocha da Silva C; Cavalcanti BC; Marinho ES; Nobre Júnior HV Microb Pathog; 2020 Nov; 148():104365. PubMed ID: 32619669 [TBL] [Abstract][Full Text] [Related]
17. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621 [TBL] [Abstract][Full Text] [Related]
19. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682 [TBL] [Abstract][Full Text] [Related]
20. Discovery of Covalent Lead Compounds Targeting 3CL Protease with a Lateral Interactions Spiking Neural Network. Gu Z; Yan Y; Liu H; Wu D; Yao H; Lin K; Li X J Chem Inf Model; 2024 Apr; 64(8):3047-3058. PubMed ID: 38520328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]